Literature DB >> 29037892

Hybrid-spheroids incorporating ECM like engineered fragmented fibers potentiate stem cell function by improved cell/cell and cell/ECM interactions.

Taufiq Ahmad1, Jinkyu Lee1, Young Min Shin2, Hyeok Jun Shin1, Sajeesh Kumar Madhurakat Perikamana1, Sun Hwa Park3, Sung Won Kim3, Heungsoo Shin4.   

Abstract

Extracellular matrix (ECM) microenvironment is critical for the viability, stemness, and differentiation of stem cells. In this study, we developed hybrid-spheroids of human turbinate mesenchymal stem cells (hTMSCs) by using extracellular matrix (ECM) mimicking fragmented fibers (FFs) for improvement of the viability and functions of hTMSCs. We prepared FFs with average size of 68.26 µm by partial aminolysis of poly L-lactide (PLLA) fibrous sheet (FS), which was coated with polydopamine for improved cell adhesion. The proliferation of hTMSCs within the hybrid-spheroids mixed with fragmented fibers was significantly increased as compared to that from the cell-only group. Cells and fragmented fibers were homogenously distributed with the presence of pore like empty spaces in the structure. LOX-1 staining revealed that the hybrid-spheroids improved the cell viability, which was potentially due to enhanced transport of oxygen through void space generated by engineered ECM. Transmission electron microscopy (TEM) analysis confirmed that cells within the hybrid-spheroid formed strong cell junctions and contacts with fragmented fibers. The expression of cell junction proteins including connexin 43 and E-cadherin was significantly upregulated in hybrid-spheroids by 16.53 ± 0.04 and 28.26 ± 0.11-fold greater than that from cell-only group. Similarly, expression of integrin α2, α5, and β1 was significantly enhanced at the same group by 25.72 ± 0.13, 27.48 ± 0.49, and 592.78 ± 0.06-fold, respectively. In addition, stemness markers including Oct-4, Nanog, and Sox2 were significantly upregulated in hybrid-spheroids by 96.56 ± 0.06, 158.95 ± 0.06, and 115.46 ± 0.47-fold, respectively, relative to the cell-only group. Additionally, hTMSCs within the hybrid-spheroids showed significantly greater osteogenic differentiation under osteogenic media conditions. Taken together, our hybrid-spheroids can be an ideal approach for stem cell expansion and serve as a potential carrier for bone regeneration. STATEMENT OF SIGNIFICANCE: Cells are spatially arranged within extracellular matrix (ECM) and cell/ECM interactions are crucial for cellular functions. Here, we developed a hybrid-spheroid system incorporating engineered ECM prepared from fragmented electrospun fibers to tune stem cell functions. Conventionally prepared cell spheroids with large diameters (>200 µm) is often prone to hypoxia. In contrast, the hybrid-spheroids significantly enhanced viability and proliferation of human turbinate mesenchymal stem cells (hTMSCs) as compared to spheroid prepared from cell only. Under these conditions, the presence of fragmented fibers also improved maintenance of stemness of hTMSCs for longer time cultured in growth media and demonstrated significantly greater osteogenic differentiation under osteogenic media conditions. Thus, the hybrid-spheroids can be used as a delivery carrier for stem cell based therapy or a 3D culture model for in vitro assay.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ECM; Fragmented fibers (FFs); Hybrid-spheroids; Osteogenic differentiation; Stem cell niche; hTMSCs

Mesh:

Year:  2017        PMID: 29037892     DOI: 10.1016/j.actbio.2017.10.022

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  10 in total

1.  Bi-functional nanoparticle-stabilized hydrogel colloidosomes as both extracellular matrix and bioactive factor delivery vehicle.

Authors:  Rui Tang; Kentaro Umemori; Jacob Rabin; Eben Alsberg
Journal:  Adv Ther (Weinh)       Date:  2020-09-07

2.  Extracellular magnetic labeling of biomimetic hydrogel-induced human mesenchymal stem cell spheroids with ferumoxytol for MRI tracking.

Authors:  Sen Yan; Ke Hu; Miao Zhang; Jingyi Sheng; Xueqin Xu; Shijia Tang; Yan Li; Sheng Yang; Guangxiang Si; Yu Mao; Yi Zhang; Feimin Zhang; Ning Gu
Journal:  Bioact Mater       Date:  2022-05-01

3.  Non-destructive monitoring of 3D cell cultures: new technologies and applications.

Authors:  Marilisa Cortesi; Emanuele Giordano
Journal:  PeerJ       Date:  2022-05-12       Impact factor: 3.061

Review 4.  Progress in scaffold-free bioprinting for cardiovascular medicine.

Authors:  Nicanor I Moldovan
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

Review 5.  Of balls, inks and cages: Hybrid biofabrication of 3D tissue analogs.

Authors:  Nicanor I Moldovan; Leni Moldovan; Michael Raghunath
Journal:  Int J Bioprint       Date:  2018-12-26

6.  Aminolysis of Various Aliphatic Polyesters in a Form of Nanofibers and Films.

Authors:  Oliwia Jeznach; Dorota Kolbuk; Paweł Sajkiewicz
Journal:  Polymers (Basel)       Date:  2019-10-14       Impact factor: 4.329

Review 7.  Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration.

Authors:  Woochan Kim; Yonghyun Gwon; Sunho Park; Hyoseong Kim; Jangho Kim
Journal:  Bioact Mater       Date:  2022-04-04

8.  Novel Mesenchymal Stem Cell Spheroids with Enhanced Stem Cell Characteristics and Bone Regeneration Ability.

Authors:  Yumi Ohori-Morita; Kunimichi Niibe; Phoonsuk Limraksasin; Praphawi Nattasit; Xinchao Miao; Masahiro Yamada; Yo Mabuchi; Yumi Matsuzaki; Hiroshi Egusa
Journal:  Stem Cells Transl Med       Date:  2022-04-29       Impact factor: 7.655

9.  Bone tissue engineering supported by bioprinted cell constructs with endothelial cell spheroids.

Authors:  WonJin Kim; Chul Ho Jang; GeunHyung Kim
Journal:  Theranostics       Date:  2022-07-11       Impact factor: 11.600

10.  Dendritic cell-mimicking scaffolds for ex vivo T cell expansion.

Authors:  Hye Sung Kim; Tzu-Chieh Ho; Moshe J Willner; Michael W Becker; Hae-Won Kim; Kam W Leong
Journal:  Bioact Mater       Date:  2022-09-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.